BioCentury
ARTICLE | Clinical News

UCB's Neupro meets in Chinese Phase III PD trial

June 17, 2015 1:01 AM UTC

UCB Group (Euronext:UCB) reported detailed data from a Phase III trial of Neupro rotigotine in Chinese patients with early stage Parkinson's disease (PD). The company announced top-line results in February. UCB plans to submit a regulatory application in China this year for the dopamine receptor agonist patch to treat PD.

Neupro met the primary endpoint of significantly improving activities of daily living (ADL) and motor function, measured by the Unified Parkinson's Disease Rating Scale (UPDRS), compared to placebo (p<0.0001). The mean change from baseline was -4.9 in the Neupro arm vs. -0.2 in the placebo arm. Neupro also led to improved individual ADL subscores (p<0.0001) and motor subscores (p=0.0004) vs. placebo. Data were presented at the Parkinson's Disease and Movement Disorders meeting in San Diego. ...